Innovator of
Microfluidics
based Drug
Delivery System

Inventage Lab incorporates Laminar FluiDigm™, its
microfluidics-based novel platform technology, into the
development of innovative Drug Delivery System (DDS).

Laminar FluiDigm ™ builds the foundation for IVL-
DrugFluidic® and IVL-GeneFluidic®, which are specific
platform technologies used for developing and
manufacturing long-acting injectables and gene
delivery therapeutics, respectively.

A various R&D pipeline of long acting injectables is
under development based on our platform technology
through incrementally modified drugs (IMD), Drug Re-
Discovery, and Joint Development programs.

With our phenomenal platform technology, we are
stepping up strategic collaboration with global partners
and expanding our reach to new businesses to
maximize our values beyond the technical limitations of
conventional DDS.

  • 0

    Year of establishment

  • 0

    Patent registration
    (Including application)

  • 0

    Pipeline

  • 0

    Development
    personnel

Contributing to improve the quality of human life
By Developing the Best DDS Platform

Innovation
Professionalism and creative innovation acquired through experience are important values to us
All scientifically verifiable ideas are highly respected.
Challenge
By constantly challenging new ideas to better technologies and overcoming the fear of failure, we aim to be a global leader with our world-leading platform technology and product.
Integrity
By pursuing reasonable and universal values, we aim for professionalism based on mutual trust based with our partners.
Respect
We aim to provide drugs of the highest quality to patients for a safe and effective treatment. Mutual respect between employees is valued at the workplace
company_img

2022

  • Joint Research Agreement for mRNA-based antibody therapeutics (APITBIO)

  • Joint Development Agreement for Alzheimer’s Disease Treatment (PRX-20016) (Prazer Therapeutics)

  • Agreement on exclusive sales and business partnership for 3M and 6M formulations of Heartworm Prevention & Treatment (IVL2001, IVL2002) (Knotus)

  • Selected for Company Specializing in Materials, Parts, and Equipment (National certification)

  • SCI Journal publication (Aesthetic Plastic Surgery)

  • SCI Journal publication(International Journal Pharmaceutics)

  • Raised Pre-IPO VC funding

  • SCI Journal publication (Aesthetic Plastic Surgery)

  • KVGMP Certified (Animal and Plant Quarantine Agency)

  • Joint Development Agreement for commercialization of LNP platform technology

  • mRNA-LNP Vaccines division: Selected for Government R&D Patent Support Program [Korea Disease Control and Prevention Agency, Korea Intellectual Property Office]

  • Raised SI VC Funding

  • DuraHeart SR-3 Injection (Moxidectin) Released

  • SCI Journal publication (Int J Pharm)

  • C.E.O., Ju Hee Kim : Government Reward for Merit in Medical Technology Advancement: 「Medical Technology Best Development Tier」 Awarded for Minister of Health and Welfare's Commendation

  • Exclusive Out-License Agreement for Prostatic Hyperplasia Treatment (IVL3013)

  • SCI Journal publication (Journal of Controlled Release)

  • Raised Series C-2 VC Funding

  • Raised SI Funding from a top tier domestic pharmaceutical company

  • CMO Agreement for Androgenic Alopecia pipeline (IVL3001, IVL3002)

  • Selected for Bio-Health Investment-Type R&D Business (Ministry of Health and Welfare)

  • Selected for 3Q/4Q IP-R&D Strategic Support Project (Korea Intellectual Property Strategy Agency)

  • IVL2001 (Heartworm Prevention and Treatment, 3M) Drug Approval

  • CMO Agreement IP for Alopecia Treatment (IVL3001, IVL3002) (Withus Pharmaceutical)

  • Agreement on Joint Development and Exclusive Usage of Technology for Alopecia Treatment (IVL3001, IVL3002) (Daewoong Pharmaceutical)

  • Selected for Inno-Biz Incorporate (National certification)

  • SCI Journal publication (International journal of molecular medicine)

  • AAPS Academic Presentation (AAPS 2019)

  • Raised Series C-1 VC funding

  • Selected for R&BD project (Ministry of Trade, Industry and Energy)

  • Series B VC funding

  • Raised Series A VC funding

  • Journal publication (BioChip Journal)

  • Selected for Domestic R&D Government Project for conditional market demand (Ministry of SMEs and Startups)

  • Obtained Medical Device GMP (level 4) plant approval

  • Selected for VC Funding-tailored R&D Project (Ministry of Science, ICT and Future Planning)

  • Raised Series Pre-A VC funding

  • Selected for R&BD Promotion Project (Ministry of Trade, Industry and Energy)

  • Inventage Lab Founded

  • Certified Venture Business (National certification) Selected for Commercialization Project Tailored to Start-Ups (Ministry of SMEs and Startups)

  • Corporate R&D Center Established(National authorized)

PARTNERS

New product commercialization is underway through various research collaborations with institutions and companies of the foremost authority.

TOTAL 16

  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo

TOTAL 5

  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo

TOTAL 7

  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo
  • partners_logo